Drug intelligence / Profile preview

TSHA-119

Development stage: Preclinical
Lead developer: Taysha Gene Therapies
Modality: Gene Therapies
Administration: Intrathecal

Overview

TSHA-119 is an AAV-based gene therapy product candidate developed by Taysha Gene Therapies in collaboration with The University of Texas Southwestern Medical Center (UT Southwestern). It is part of a pipeline of gene therapies aimed at treating monogenic diseases of the central nervous system. The drug originated from the foundational partnership between Taysha and UT Southwestern's Gene Therapy Program.

Targets

GM2A (Ganglioside GM2 activator)

Beyond the preview

Go deeper on TSHA-119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSHA-119.

Explore the full profile